Page 5 - Indian Pharma Companies

Aurobindo Pharma receives USFDA approval to manufacture Darunavir tablets

Darunavir Tablets, 600 mg, and 800 mg, in combination with other antiretroviral agents, are indicated for the treatment of (HIV-1) infection in adult and pediatric patients 3 years of age and older

Pharma majors turn attention to OTC drugs in post-pandemic wellness shift

Building a healthy OTC brand, however, is not an easy task. OTC brands need time to grow and build a recall value once they have established some credibility

Mankind Pharma Q2 results: Consolidated net profit rises 21% to Rs 511 cr

Mankind Pharma on Tuesday said its consolidated net profit increased by 21 per cent to Rs 511 crore for the second quarter ended September 30, 2023, on the back of robust performance across segments. The company had reported a net profit of Rs 422 crore in the July-September period of the last fiscal. Revenue from operations rose to Rs 2,708 crore in the period under review from Rs 2,425 crore in the year-ago period, Mankind Pharma said in a regulatory filing. "The past strategic choices in various aspects of our business are showing success, and we are confident in our ability to consistently surpass the industry growth in future," Mankind Pharma Vice Chairman & Managing Director Rajeev Juneja said. Shares of Mankind Pharma on Tuesday ended 0.7 per cent lower at Rs 1,741.10 apiece on the BSE.

AI startup Leucine gets $7 mn funding from Ecolab Inc, angel investors

Leucine's platform can be rolled out in as little as eight weeks, thanks to its proprietary AI-enabled digital process builder

Generic medicines: Indian pharma market is at crossroads of systemic shift

Companies must start preparing their business models to adjust to the reality of the shift to medical practitioners prescribing only generic molecule names

Strides Pharma Q1FY24 results: Net profit at Rs 8 cr; revenue up 12%

The total income for Q1FY24 came in at Rs 486.9 crore, compared to Rs 430.6 crore year-on-year

Indian firm used toxic industrial-grade ingredient in cough syrups

The two sources said the syrup was made with industrial-grade PG, a toxic material widely used in liquid detergents, antifreeze, paints or coatings, and to enhance the effectiveness of pesticides

Facing higher scrutiny, IPA plans monthly meetings with members on quality

Data suggests that Indian sites received fewer OAIs in the first six months of 2023

Gambia tightens drug import rules for India after mass deaths from July 1

A report by a team of international experts blamed tainted medicine from India for an outbreak of kidney failure that killed more than 60 Gambian children last year

Pharma firms may soon be required to mention excipients on medicine strips

As of now the labels on medicines only declare active substances, which are added to the formulation

Janus Henderson further downgrades PharmEasy valuation to $ 2.7 billion

Several other Indian startups such as Meesho, Swiggy, Byju's, Pine Labs, and Ola have seen similar cuts in their valuations

Natco Pharma to set up subsidiary in Indonesia with investment of $3 mn

Natco Pharma Ltd on Thursday said its board has approved setting up of a subsidiary in Indonesia with an investment of up to USD 3 million (nearly Rs 25 crore) for selling pharmaceutical products in that country. The new subsidiary -- PT. NATCO Lotus Farma -- will be a joint venture with Natco holding 51 per cent and the balance stake 49 per cent by PT. Mitra Medis Exim (MME), a part of Mitra Jaya Group, which is a 40 year old multi-diversified group, as the co-promoter, the company said in a regulatory filing. The company's board approved the proposal at its meeting held on Thursday. Natco will initially invest USD 1 million for a stake of 51 per cent as capital contribution and balance will be invested as and when the funds are required by the subsidiary, it added. PT. NATCO Lotus Farma will be engaged in selling pharmaceutical products in Indonesia, it added. MME is in the business of distribution for active pharmaceutical ingredients and excipients for end-users in Indonesia.

Health min urges stakeholders to build trust in quality of Indian drugs

Union Health Minister Mansukh Mandaviya urged all the stakeholders on Sunday to steadfastly work towards building trust and confidence in the quality of Indian drugs, cosmetics and medical devices in domestic and export markets. It is of critical importance to ensure that the country's regulatory mechanisms are of impeccable standards that are sustained over time and space, Mandaviya said as he inaugurated a two-day "chintan shivir" on "Drugs: Quality Regulations and Enforcement" in Hyderabad. "How can we ensure that the confidence of the consumers of pharmaceuticals manufactured in India is upheld? I urge all the stakeholders to steadfastly work towards making the Indian drugs regulatory system among the best in the world, which could be emulated by other countries," he said. In his inaugural address, Mandaviya underlined the focus of the deliberative forum, saying, "The chintan shivir is a platform for all the stakeholders in the pharma and health sectors to deliberate on pathways

Lupin Pharma launches Lurasidone Hydrochloride Tablets in US

The generic equivalent of Latuda tablets has been launched in the US markets

Timely resolution of FDA action crucial to Indian pharma's US pipeline

Analysts say overall risks remain high for US generics business

India starts probe after Uzbekistan cough syrup deaths, Noida firm responds

According to the ministry, chemical ethylene glycol was found in a batch of syrup during laboratory tests

After Gambia, now Uzbekistan alleges Indian cold drug killed its children

Noida-based Marion Biotech's Dok-1 Max anti-cold medicine under scanner after the Central Asian nation blames it for 18 deaths

Fosun plans to sell of India's $3.8 billion drug maker Gland Pharma

Fosun Pharma, a listed arm of Chinese conglomerate Fosun International Ltd., has been working with an adviser as it informally gauges interest in its controlling stake in Gland, the people said

Cipla Q2 PAT up 11% PAT to Rs 789 cr on strong Covid-adjusted growth rate

The company is de-risking key product Abraxane in case the Goa plant FDA issue is not cleared immediately

Pharma marketing practices: High-level committee to meet industry on Friday

The UCPMP is voluntary and there is no legal penalty for violating the code